Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
2–14
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Bone age less than or equal to (\</=) 8 years (females) or \</= 10 years (males) as determined by x-ray of the left hand and wrist obtained within six months before enrollment
Prepubertal males and females by physical exam
Naive to rhGH therapy
Diagnosis of IGHD or ISS by standard pharmacologic testing and no other discernable etiology for short stature
Height standard deviation score (Ht SDS) \</= -1.5 (\</= 5th percentile) for IGHD participants; Ht SDS \</= -2.25 (\</= 1.2 percentile) for ISS participants
You may not be if
Short stature etiologies other than IGHD or ISS
Participants receiving chronic corticosteroid therapy (greater than \[\>\] 3 months) for other medical conditions
Participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated
Females with turner syndrome
Any previous rhGH treatment
Participation in another simultaneous medical investigation or trial
Pediatric participants with closed epiphyses
Participants prescribed rhGH doses outside the variance of NCGS control participant dosing
Clareo Health | A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
